Meghan Thompson

8PUBLICATIONS
107CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Medical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 22, 2026
Molecular and Structural Basis of Pan-Resistance to BTK Degraders and Inhibitors.

|Jun 30, 2026
Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

|Dec 06, 2025
Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure.

Kuo-Kai Chin, Brian J Ball, Yasmin Abaza

|Nov 19, 2024
Consensus recommendations from the 2024 Lymphoma Research Foundation workshop on treatment selection and sequencing in CLL or SLL.

Jacob D Soumerai, Jacqueline Barrientos, Inhye Ahn

|Aug 09, 2024
Real-world incidence and prevention of tumor lysis syndrome in chronic lymphocytic leukemia treated with venetoclax.

Yannis K Valtis, David Nemirovsky, Andriy Derkach

|Feb 01, 2024
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127.

Skye Montoya, Jessie Bourcier, Mark Noviski

Pageof 2

Frequent Collaborators

5 joint publications

Lindsey Roeker

3 joint publications

Mark B Geyer

3 joint publications

Andrew Zelenetz

2 joint publications

Ratul Mukerji